Klin Farmakol Farm. 2010;24(4):187-189

Daptomycin - a new antibiotic for the treatment of serious infections caused by certain gram-positive bacteria

Vilma Marešová1, Pavla Urbášková2
1 Fakultní nemocnice Na Bulovce, I. infekční klinika, 2 LF UK Praha
2 Národní referenční laboratoř pro antibiotika, Státní zdravotní ústav Praha

Daptomycin is a cyclic polypeptide, a new antibiotic with bactericidal activity in vitro against many gram-positive bacteria. This well-tolerated

antibiotic is used for intravenous treatment of serious infections caused by staphylococcus and streptococcus, or strains, resistant

and multidrug-resistant to other antibiotics. The indication for daptomycin include serious skin and soft tissues, including forms and

right bakteremických endocarditis caused by Staphylococcus aureus.

Keywords: daptomycin, the effect in vitro, using

Published: December 31, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marešová V, Urbášková P. Daptomycin - a new antibiotic for the treatment of serious infections caused by certain gram-positive bacteria. Klin Farmakol Farm. 2010;24(4):187-189.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Khatib R, Saeed S, Sharma M, et al. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25: 181-185. Go to original source... Go to PubMed...
    2. Gemmel CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608. Go to original source... Go to PubMed...
    3. Horstkotte D, Follath F, Gutschik E, et al. Guidelines on prevention, diagnosis and treatment of infectious endocarditis: executive summary. The Task Force on Infective Endocarditis of the European Society of Cardiology. Eur Heart 2004; 25: 267-276. Go to original source... Go to PubMed...
    4. Aeschlimann JR, Hershberger E, Rybak MJ. Analysis of population susceptibility profiles, killing activity and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1914-1918. Go to original source... Go to PubMed...
    5. Alborn WE, Allen NE, Preston, DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 2282-2287. Go to original source... Go to PubMed...
    6. Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of inicial killing and postantibiotic effect and influence of Ca+ and albumin on these drugs. Antimicrob Agents Chemother 1991; 35: 1710-1716. Go to original source... Go to PubMed...
    7. Bush LM, Boscia JA, Wendeler M, et al. In vitro postantibiotic effect of daptomycin (LY 146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1989; 33: 1198-1200. Go to original source... Go to PubMed...
    8. Roveta S, Marchese A, Schito GC. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int J Antimicrob Agents 2008; 31: 321-328. Go to original source... Go to PubMed...
    9. Marco F, García de la Mária C, Armero Y, et al. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2538-2543. Go to original source... Go to PubMed...
    10. EARSS. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2008. Dostupné na http://www.rivm.nl/earss/Images/EARSS%202008_final_tcm6165020.pdf.
    11. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 2137-2145. Go to original source... Go to PubMed...
    12. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454-459. Go to original source... Go to PubMed...
    13. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug. Antimicrob Agents Chemother 2008; 52: 269-278. Go to original source... Go to PubMed...
    14. EUCAST technical note on daptomycin. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. Clin Microbiol Infect 2006; 12: 599-601. Dostupné také na http://www.eucast.org/fileadmin/src/media/PDFs/4ESCMID_Library/3Publications/EUCAST_Documents/Technical_Notes/EUCAST_clm_1455.pdf.
    15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI Document M100-S20. Clinical and Laboratory Standards Institute, USA, Pa, 2010.
    16. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1,1 April 2010; dostupné na http://www.eucast.org/clinical_breakpoints/.
    17. Sakoulas G, Brown J, Lamp KC, et al. Clinical outcomes of patiens receiving daptomycin for the treatment of Staphylococcus aureus infection and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin outcomes registry and experience. Clin Ther 2009; 31: 1936-1945. Go to original source... Go to PubMed...
    18. EMEA. Cubicin Summary Product Characteristic. http://www.ema.europa.eu/docs/en_GB/document_library/EPARProduct_Information/human/000637/WC500036049.pdf.
    19. EUCAST European Committee on Antimicrobial Susceptibility Testing. MIC distributions. Dostupné na http://www.eucast.org/mic_distributions/.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.